Literature DB >> 12549642

Immunopathological prognostic and predictive factors in prostate cancer.

E Sivridis1, S Touloupidis, A Giatromanolaki.   

Abstract

Prostate cancer is the leading male malignancy in the Western world. Patients with prostate cancer have an unpredictable clinical course, as three biologically different types of tumor exist. This review summarises some of the recent progress made in understanding the biology of prostate cancer with special reference to the prognostic and predictive role of immunohistochemical markers. The prognostic value of established prognostic variables is also discussed.

Entities:  

Mesh：

Year:  2002        PMID： 12549642     DOI： 10.1023/a:1021306928664

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN： 0301-1623            Impact factor:   2.370


  112 in total

1.  Autonomous growth of androgen-independent human prostatic carcinoma cells: role of transforming growth factor alpha.

Authors:  D R Hofer; E R Sherwood; W D Bromberg; J Mendelsohn; C Lee; J M Kozlowski
Journal:  Cancer Res       Date:  1991-06-01       Impact factor: 12.701

2.  Differential expression of C-CAM cell adhesion molecule in prostate carcinogenesis in a transgenic mouse model.

Authors:  Y S Pu; W Luo; H H Lu; N M Greenberg; S H Lin; J R Gingrich
Journal:  J Urol       Date:  1999-09       Impact factor: 7.450

3.  Ki-67 expression in early prostate cancer and associated pathological lesions.

Authors:  M R Feneley; M P Young; C Chinyama; R S Kirby; M C Parkinson
Journal:  J Clin Pathol       Date:  1996-09       Impact factor: 3.411

4.  Tumor angiogenesis is associated with MUC1 overexpression and loss of prostate-specific antigen expression in prostate cancer.

Authors:  I Papadopoulos; E Sivridis; A Giatromanolaki; M I Koukourakis
Journal:  Clin Cancer Res       Date:  2001-06       Impact factor: 12.531

5.  Prostate cancer.

Authors:  R E Frank
Journal:  J Insur Med       Date:  2001

6.  Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer.

Authors:  D Strohmeyer; C Rössing; A Bauerfeind; O Kaufmann; H Schlechte; G Bartsch; S Loening
Journal:  Prostate       Date:  2000-11-01       Impact factor: 4.104

7.  Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers.

Authors:  M Colombel; F Symmans; S Gil; K M O'Toole; D Chopin; M Benson; C A Olsson; S Korsmeyer; R Buttyan
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

8.  Observations on the number, size and localization of nucleoli in hyperplastic and neoplastic prostatic disease.

Authors:  B Helpap
Journal:  Histopathology       Date:  1988-08       Impact factor: 5.087

9.  Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup.

Authors:  J I Epstein; M Carmichael; A W Partin; P C Walsh
Journal:  J Urol       Date:  1993-06       Impact factor: 7.450

10.  Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components.

Authors:  J Wesseling; S W van der Valk; H L Vos; A Sonnenberg; J Hilkens
Journal:  J Cell Biol       Date:  1995-04       Impact factor: 10.539
View more
  1 in total

1.  ADAM8 expression in prostate cancer is associated with parameters of unfavorable prognosis.

Authors:  Florian R Fritzsche; Monika Jung; Chuanliang Xu; Anja Rabien; Hanka Schicktanz; Carsten Stephan; Manfred Dietel; Klaus Jung; Glen Kristiansen
Journal:  Virchows Arch       Date:  2006-11-08       Impact factor: 4.064
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.